The Latest Breaking News from Amgen

Even though Amgen is weak below the 200-day line, there's still a way to profit.

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.48%. Stocks today are mixed, with some positive corporate news lifting the broader market. JM...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.

Amgen's Phase 2 MariTide trial showed ~20% weight loss at 52 weeks, cardiometabolic improvements, and no significant safety issues.

With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range.

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral density loss.

Amgen is focusing deeply on its efforts to treat obesity, the CFO said Wednesday. Amgen stock rose early Thursday.